Jeff Dykan has served on the ReWalk board since 2006 and has been its Chairman since 2009. Mr. Dykan has been a director of the corporate general partner of the common general partner of Vitalife and its successor fund, SCP Vitalife, an Israeli venture capital fund, since 2002 and 2007, respectively. Prior to joining Vitalife, from 2001 to 2002, Mr. Dykan was the Chairman and Chief Executive Officer of BitBand Inc. Mr. Dykan is a member of the American Institute of CPAs and holds a B.Sc. in accounting and management and an MBA in computer applications, both from New York University.
CEO & Director
Larry Jasinski has served as Chief Executive Officer and as a member of the ReWalk board since February 2012. From 2005 until 2012, Mr. Jasinski served as the President and Chief Executive Officer of Soteira, Inc., a company engaged in development and commercialization of products used to treat individuals with vertebral compression fractures, which was acquired by Globus Medical in 2012. From 2001 to 2005, Mr. Jasinski was President and Chief Executive Officer of Cortek, Inc., a company that developed next-generation treatments for degenerative disc disease, which was acquired by Alphatec in 2005. From 1985 until 2001, Mr. Jasinski served in multiple sales, research and development, and general management roles at Boston Scientific Corporation. Mr. Jasinski holds a B.Sc. in marketing from Providence College and an MBA from the University of Bridgeport.
Yasushi Ichiki has served on the ReWalk board since 2014. Mr. Ichiki has been the Manager of the Corporate Planning Group, Corporate Planning Division, of Yaskawa Electric Corporation since May 2014. Previously, from February 2010 to April 2014, he served as the General Manager of Corporate Planning, Robotics Division of Yaskawa Europe GmbH. Mr Ichiki holds a B.A. from Yamaguchi University, Japan.
Wayne B. Weisman
Wayne B. Weisman has served on the ReWalk board since 2009. Since 2007, Mr. Weisman has been a director of the corporate general partner of the common general partner of SCP Vitalife. He has also served as a managing member of SCP Vitalife Management Company, LLC, which by contract provides certain management services to the common general partner of SCP Vitalife. Mr. Weisman is Chairman of Recro Pharma, Inc. (Nasdaq: REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain. He also serves on the board of a number of private companies, including Recro Pharma, LZ Therapeutics and Echo 360. He is Chairman of the board of trustees of Young Scholars School. Mr. Weisman holds a B.A. from the University of Pennsylvania and a J.D. from the University of Michigan Law School.
Dr. John William Poduska
Dr. John William Poduska will serve on the ReWalk board starting in September 2014 as an external director. Dr. Poduska currently serves as a director of EXA Corporation (NASDAQ: EXA) where he serves as chairman of the compensation committee and a member of the nominating and governance committee. He also serves as a director on the boards of a number of privately-held companies. Dr. Poduska also served as a director of Novell, Inc. until 2011 and of Anadarko Petroleum Corporation and Safeguard Scientifics, Inc. until 2009. Dr. Poduska was the Chairman of Advanced Visual Systems Inc., a provider of visualization software, from January 1992 to December 2001. From December 1989 until December 1991, Dr. Poduska was President and Chief Executive Officer of Stardent Computer Inc., a computer manufacturer. From December 1985 until December 1989, Dr. Poduska served as Chairman and Chief Executive Officer of Stellar Computer Inc., a computer manufacturer he founded which is the predecessor of Stardent Computer Inc. Prior to founding Stellar Computer, Inc., Dr. Poduska founded Apollo Computer Inc. and Prime Computer, Inc. Dr. Poduska holds a Sc.D. from MIT and an Honorary Doctorate of Humane Letters from Lowell University.
Pete Wehrly previously served in multiple senior roles at Covidien plc (“Covidien”), including Group President of Developed Markets and Group President of Respiratory & Monitoring Solutions and Vascular Therapies, from 2009 until 2015, during which Covidien was a public company listed on the New York Stock Exchange. Prior to joining Covidien, Pete served as President and Chief Executive Officer at Medingo Ltd. an Israel based company from 2008-2009. From 2000 to 2008 he held senior executive-level roles at Medtronic Spinal and Biologics in Memphis, Tennessee, where he oversaw the global market expansion of that company’s core spinal fusion therapies, minimal access technologies, motion-sparing devices and biologic technologies. Prior to that, he spent 17 years at DePuy, a division of Johnson & Johnson, and served as DePuy’s Sports Medicine Division President from 1997 to 2000. Throughout his career at various companies, Pete headed regional strategies to gain regulatory approval and reimbursement for new technologies in Europe, Japan, Australia, New Zealand, the United States and Canada. In addition, since 2012, he has been a director of Non Linear Technologies Ltd. Pete holds a Bachelor of Science in Management from Ball State University in Muncie, Indiana and has been a member of a number of community boards.
Yohanan Engelhardt joined the ReWalk board in 2018. Mr. Engelhardt has served as CFO and VP finance of publicly-traded and private companies for 28 years, including 18 years at ViryaNet, a provider of mobile workforce management software solutions. During his tenure at ViryaNet he oversaw all financial operations, M&A activities, private placements, the company’s IPO and the sale of the company to a large private equity firm in 2014. Since 2015, he has provided CFO services to early-stage technology and medical device companies as well as accounting services to an accounting firm.
Mr. Engelhardt holds a B.A. in accounting and economics from the Hebrew University of Jerusalem and CPA certifications in the U.S. and in Israel. He is a member of the American Institute of CPAs and the Institute of CPAs in Israel.
Chunlin (Allen) Han
Mr. Han is an executive director of Liquid Harmony Limited and serves as Head of Investment and Financing for Realcan Pharmaceutical Group Co. Ltd. (Shenzen: 002589.SZ), a large distributor of medical drugs and equipment in China with access to more than 8,000 hospitals and 33,000 primary medical institutions, where he has been instrumental in acquiring more than 50 distribution companies and participated in three joint venture investments. Mr. Han holds a Bachelor of Science degree in pharmacology from McGill University in Montreal, Canada. His father, Xu Han, and his mother, Renhua Zhang, indirectly control Timwell affiliate Realcan Ambrum Healthcare Industry Investment (Shenzhen) Partnership Enterprise (Limited Partnership), and Mr. Xu Han is the sole shareholder of Timwell.